[1]黄春玲,查金顺,蒋婷吟.甲状腺功能亢进症患者血浆中TNF-α1和IL-2水平的临床分析[J].国际放射医学核医学杂志,2012,36(2):92-93,120.[doi:10.3760/cma.j.issn.1673-4114.2012.02.008]
　HUANG Chunling,ZHA Jin-shun,JIANG Ting-yin.The clinical analysis of the TNF-α1 and IL-2 levels in patients with hyperthyroidism[J].International Journal of Radiation Medicine and Nuclear Medicine,2012,36(2):92-93,120.[doi:10.3760/cma.j.issn.1673-4114.2012.02.008]
点击复制

甲状腺功能亢进症患者血浆中TNF-α1和IL-2水平的临床分析(/HTML)
分享到：

《国际放射医学核医学杂志》[ISSN:1673-4114/CN:12-1381/R]

卷:
36
期数:
2012年第2期
页码:
92-93,120
栏目:
临床核医学
出版日期:
2012-03-25

文章信息/Info

Title:
The clinical analysis of the TNF-α1 and IL-2 levels in patients with hyperthyroidism
作者:
黄春玲;  查金顺;  蒋婷吟
福建医科大学附属第二医院核医学科, 泉州 362000
Author(s):
HUANG Chunling;  ZHA Jin-shun;  JIANG Ting-yin
Department of Nuclear Medicine, the Second Affiliated Hospital of Fujian Medical University, Quanzhou 362000, China
关键词:
甲状腺功能亢进症; 肿瘤坏死因子α; 白细胞介素1; 放射免疫测定
Keywords:
Hyperthyroidism; Tumor necrosis factor-alpha; Interleukin-1; Radioimmunoassay
DOI:
10.3760/cma.j.issn.1673-4114.2012.02.008
摘要:
目的 探讨Graves病(GD)、Hashimoto病(HD)等不同病因引起的甲状腺功能亢进症(简称甲亢)患者血浆中肿瘤坏死因子α1(TNF-α1)和白细胞介素2(IL-2)水平的变化特点.方法 将250例甲亢患者分为3组,其中,GD组109例、HD组80例、其他病因组61例.正常对照组为98名健康正常人.采用放射免疫分析法检测所有患者及健康正常人血浆中TNF-α1和IL-2的水平.结果 250例甲亢患者中,GD组和HD组的TNF-α1水平明显高于其他病因组(dTNF-α1=17.638和19.248,P均<0.01)和正常对照组(dTNF-α1=24.460和26070,P均<0.01);IL-2水平则是明显低于其他病因组(dIL-2=2.668和2.975,P均<0.01)和正常对照组(dIL-2=2.649和2.955,P均<0.01).其他病因组和正常对照组间的TNF-α1和IL-2水平差异均无统计学意义(dTNF-α1=0.821,dIL-2=0.194,P均>0.05).结论 GD、HD等白身免疫性甲状腺疾病的发生和发展伴有血浆TNF-α1、IL-2水平的改变,而高碘摄取、毒性多结节性甲状腺肿和毒性腺瘤等原因所致甲亢患者的血浆TNF-α1、IL-2水平则无特殊变化.血浆中TNF-α1和IL-2水平的检测分析对于GD和HD的鉴别诊断和疗效评价具有重要的临床意义。
Abstract:
Objective To explore the characters of plasma levels of the tumor nccrosis factor-α1 (TNF-α1) and interleukin-2 (IL-2) in patients with hyperthyroidism due to multiple etiologies such as Graves disease(GD) and Hashimoto disease(HD) etc.Methods Two hundred and fifty hyperthyroidism patients were divided into three groups,including GD group (n=109),HD group (n=80) and other causes of hyperthyroidism group (n=61).Ninty-eight healthy individuals served as control group.The TNF-α1 and IL-2 levels in plasma were measured by radioimmunoassay.Results The TNF-α1 level in plasma of GD group and HD group were significantly higher than that of other causes of hyperthyroidism group (dTNF-α1=17.638 and 19.248,both P<0.01) and normal group (dTNF-α1=24.460 and 26.070,both P<0.01).The IL-2 level in plasma of GD group and HD group were significantly lower than that of other causes of hyperthyroidism group (dIL-2=2.668 and 2.975,both P<0.01) and normal group (dIL-2=2.649 and 2.955,both P<0.01).There were no significant differences of the TNF-α1 and IL-2 levels in plasma between other causes of hyperthyroidism group and normal group(dTNF-α1=0.821,dIL-2=0.194,both P>0.05).Conclusions Hyperthyroidism due to autoimmune disease such as GD and HD accompanied with changes of TNF-α1 and IL-2 levels in plasma,while hyperthyroidism due to high iodine uptake,toxic multinodular goiter,and toxic adenoma did not accompany with changes of TNF-α1 and IL-2 levels in plasma.The plasma levels of TNF-α1 and IL-2 may play an important role in differential diagnosis and therapeutic effect evaluation in GD and HD.

参考文献/References:

[1] 中华医学会内分泌分会《中国甲状腺疾病诊治指南》编写组.中国甲状腺疾病诊治指南——甲状腺功能亢进症.中华内科杂志,2007,46(10):876-882.
[2] 叶任高.陆再英.内科学.6版.北京:人民卫生出版社,2006:725.
[3] 施秉银,马秀萍.现代甲状腺疾病诊断与治疗.西安:陕西科学技术出版社,1998:103.
[4] 滕云,林汉华.肿瘤坏死因子,白细胞介素-1对鼠甲状腺激素的影响.放射免疫学杂志,1999,12(3):129-130.
[5] 杨宝中,孙君江.Graves病患者外周血IL-2水平探讨.放射免疫学杂志,1998,11(3):184-185.
[6] 朱学文.甲亢患者治疗前后血清FT3、FT4和IL-2水平的变化及临床意义.放射免疫学杂志,2011,24(1):21-22.
[7] 尹伯元.放射免疫分析在医学中的应用.北京:原子能出版社,1991.491-421.
[8] 徐芳,吴澄, 何浩明.婴幼儿感染性疾病患儿TNF,IL-2水平及其临床意义.放射免疫学杂志,1999,12(4):242-243.

相似文献/References:

[1]梁雯丽,郑艳,李娜,等.Graves甲亢患者131I治疗后早期TRAb及TSAb变化的研究分析[J].国际放射医学核医学杂志,2016,40(1):13.[doi:10.3760/cma.j.issn.1673-4114.2016.01.003]
　Liang Wenli,Zheng Yan,Li Na,et al.Analysis of the changes in early TRAb and TSAb after 131I treatment for patients with Graves hyperthyroidism[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(2):13.[doi:10.3760/cma.j.issn.1673-4114.2016.01.003]
[2]田琦,蒋宁一,郑丽.265例精细个体化131I治疗Graves甲亢的疗效观察[J].国际放射医学核医学杂志,2016,40(4):259.[doi:10.3760/cma.j.issn.1673-4114.2016.04.004]
　Tian Qi,Jiang Ningyi,Zheng Li.Therapeutic effect of fine individual 131I treatment on Graves disease hyperthyroidism[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(2):259.[doi:10.3760/cma.j.issn.1673-4114.2016.04.004]
[3]王越,晋建华,李思进,等.甲状腺24h摄碘率与131I治疗Graves甲亢疗效相关性研究[J].国际放射医学核医学杂志,2015,39(6):442.[doi:10.3760/cma.j.issn.1673-4114.2015.06.002]
　Wang Yue,Jin Jianhua,Li Sijin,et al.Correlation between thyroid 24 h of radioactive iodine uptake and clinical efficacy of 131I therapy for Graves’ hyperthyroidism[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(2):442.[doi:10.3760/cma.j.issn.1673-4114.2015.06.002]
[4]张丽花,蒋宁一.131I治疗Graves甲亢合并肝功能损害或血细胞减少的优势与风险[J].国际放射医学核医学杂志,2015,39(6):483.[doi:10.3760/cma.j.issn.1673-4114.2015.06.010]
　Zhang Lihua,Jiang Ningyi.The advantage and risk of 131I treatment in hyperthyroidism combined with liver injury or blood cell reduction[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(2):483.[doi:10.3760/cma.j.issn.1673-4114.2015.06.010]
[5]杨宝军.131I治疗甲亢合并特发性血小板减少性紫癜一例[J].国际放射医学核医学杂志,2015,39(6):511.[doi:10.3760/cma.j.issn.1673-4114.2015.06.017]
[6]郭坤,高蕊,于燕,等.表皮生长因子受体基因表达与甲状腺功能亢进症131I治疗预后的关系[J].国际放射医学核医学杂志,2015,39(1):4.[doi:10.3760/cma.j.issn.1673-4114.2015.01.003]
　Guo Kun,Gao Rui,Yu Yan,et al.The relationship between epidermal growth factor receptor mRNA expression and the efficacv of 131I treatment in hyperthyroidism patients[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(2):4.[doi:10.3760/cma.j.issn.1673-4114.2015.01.003]
[7]赵若愚,鲍逸民,杨永青.血浆心肌细胞损伤标志物检测急性心肌梗死患者心肌损伤的临床研究[J].国际放射医学核医学杂志,2014,38(4):235.[doi:10.3760/cma.j.issn.1673-4114.2014.04.007]
　Zhao Ruoyu,Bao Yimin,Yang Yongqing.The clinical study of plasma myocardial cell damage markers in detecting myocardial injury patients with acute myocardial infraction[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(2):235.[doi:10.3760/cma.j.issn.1673-4114.2014.04.007]
[8]张瑞国,秦岚,张又萍,等.初诊Graves甲亢合并肝损害及其影响因素的临床分析[J].国际放射医学核医学杂志,2013,37(5):283.[doi:10.3760/cma.j.issn.1673-4114.2013.05.008]
　ZHANG Rui-guo,QIN Lan,ZHANG You-ping,et al.Clinical study of hepatic dysfunction and its correlative factors in newly diagnosed patients with Graves hyperthyroidism[J].International Journal of Radiation Medicine and Nuclear Medicine,2013,37(2):283.[doi:10.3760/cma.j.issn.1673-4114.2013.05.008]
[9]路璐,李德冠,王月英,等.脂多糖对受照小鼠血清IL-10、IL-6和TNF-α水平的影响[J].国际放射医学核医学杂志,2012,36(3):154.[doi:10.3760/cma.j.issn.1673-4114.2012.03.008]
　LU Lu,LI De-guan,WANG Yue-ying,et al.Effects of lipopolysaccharide on IL-10, IL-6 and TNF-α levels in radiation-exposed mice[J].International Journal of Radiation Medicine and Nuclear Medicine,2012,36(2):154.[doi:10.3760/cma.j.issn.1673-4114.2012.03.008]
[10]孙启和,孙彬,杨永青.冠心病患者血清细胞因子和超敏C-反应蛋白水平测定的临床意义[J].国际放射医学核医学杂志,2010,34(5):291.[doi:10.3760/cma.j.issn.1673-4114.2010.05.010]
　SUN Qi-he,SUN Bin,YANG Yong-qing.Clinical application of changes of serum cytokines and hypersensitive C-reactive protein in patients with coronary heart disease[J].International Journal of Radiation Medicine and Nuclear Medicine,2010,34(2):291.[doi:10.3760/cma.j.issn.1673-4114.2010.05.010]

备注/Memo

备注/Memo:
收稿日期:2012-01-12。
通讯作者:查金顺,Email:zjs630805@126.com
更新日期/Last Update: 1900-01-01